塞拉德尔帕用于治疗初级胆管胆道炎
Adonice P Khoury1, Jason Powell1
1Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Gainesville, FL, USA.
The Annals of pharmacotherapy
|March 12, 2025
概括
塞拉德尔帕是一种PPARδ激动剂,通过改善生化标志物和减少,在治疗一次性胆道胆道炎 (PBC) 中表现有前途. 它为患有未满足PBC管理需求的患者提供了安全有效的选择.
科学领域:
- 肝病学和胃肠病学 肝病学和胃肠学
- 药理学和治疗学 药理学和治疗学
- 药物开发 药物开发
背景情况:
- 原发性胆道胆炎 (PBC) 是一种慢性肝病,现有的治疗方法并不能在所有患者中获得最佳的结果.
- 对于改善生化反应和缓解PBC中等症状的疗法,存在着未得到满足的需求.
- 塞拉德尔帕是一种新的治疗方法,其向的是氧酶增殖器激活受体三角 (PPARδ) 途径.
研究的目的:
- 审查和综合关于seladelpar.com的药理学,疗效和安全性的已公布数据.
- 评估seladelpar在解决初级胆道胆炎 (PBC) 治疗未满足需求方面的潜在作用.
- 评估seladelpar在PBC的FDA加速批准后的地位.
主要方法:
- 在PubMed,谷歌学者和NIH临床试验注册表的综合文献搜索.
- 包括从1985年1月1日到2025年1月27日的英语语言学习.
- 审查的重点是seladelpar在PBC中的药理学,药理动力学,安全性和疗效.
主要成果:
- 与安慰剂相比,塞拉德尔帕显著改善了生化反应,性酸酶 (ALP) 正常化和.
- 该药物表现出良好的安全性和耐受性.
- 塞拉德尔帕显示出作为一种附加疗法的潜力,以提高PBC患者的治疗结果.
结论:
- 塞拉德尔帕是一种安全有效的初级胆道胆炎 (PBC) 治疗选择,解决了重大未满足的医疗需求.
- 药物的临床益处,预测由代用终点,可能需要进一步确认,以获得完整的FDA批准.
- 塞拉德尔帕提供了一种有前途的新治疗途径,用于管理PBC并改善患者的生活质量.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
54
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
54
01:29Drugs for Treatment of Ulcerative Colitis in IBD
115
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115
01:17Drugs for Treatment of Diarrhea-Predominant IBS
133
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
133
01:22Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141
01:26Peptic Ulcer Disease IV: Management
56
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
56
01:17Chronic Bowel Disorders: Introduction
375
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
375